Immuneering reports Q4 2022 net loss $13.2M; cash runway into Q4 2024; first patient dosed in IMM-1-104 trial

Immuneering Corp

Net loss $13.2M ($0.50/share) for Q4 2022 vs $10.8M ($0.42/share) in Q4 2021; full year net loss $50.5M ($1.91/share).
Cash, cash equivalents and marketable securities $105.5M as of Dec 31, 2022; cash runway extended into Q4 2024 after suspending neuroscience programs.
First patient dosed in Phase 1/2a trial of IMM-1-104 for advanced solid tumors with any RAS mutation; initial PK/safety data expected mid-2023.
IND filing for IMM-6-415 expected Q4 2023; preclinical data presented at SITC 2022.
R&D expenses $9.9M in Q4 2022 vs $7.9M in Q4 2021; G&A $4.1M vs $3.1M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immuneering Corp reported financial results for the quarter and full-year ended December 31, 2022.

Period: the quarter and full-year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 6, 2023, Immuneering Corporation (the “Company”) announced its financial results for the quarter and full-year ended December 31, 2022 and provided business updates.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Immuneering Corp filing history →

Source: SEC EDGAR

accession 0001558370-23-002901

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.